From Tryptophan to Psilocybin: The Enzymatic Journey

Psilocybin Biosynthesis

4 enzymes

In 2017, Fricke and colleagues identified all four enzymes responsible for psilocybin biosynthesis and demonstrated enzymatic synthesis of psilocybin in a single test-tube reaction — the founding moment for pharmaceutical-scale psilocybin production.

Fricke, Blei & Hoffmeister, Angew Chem Int Ed, 2017

5 steps

from tryptophan to psilocybin, via tryptamine, 4-hydroxytryptamine, norbaeocystin, and baeocystin

0.9 Å resolution

Hudspeth 2024 crystal structure of PsiM reveals why the pathway stops at exactly two methylations

2 sequential methylations

PsiM performs both the norbaeocystin→baeocystin and baeocystin→psilocybin reactions

Fricke, Blei & Hoffmeister, Angew Chem Int Ed, 2017

View as image ↗

Tryptophan is one of the nine essential amino acids your body cannot make on its own. It is in every protein-containing food. Your body uses it to make serotonin. Certain mushrooms use it, through a completely different chemical sequence, to make psilocybin. The difference between those two outcomes comes down to four enzymes and five steps in what is now known as the tryptophan-to-psilocybin biosynthetic pathway.

This pathway was fully characterized in 2017, when Fricke, Blei, and Hoffmeister identified all four enzymes from Psilocybe cubensis and demonstrated that psilocybin could be synthesized in a one-pot enzymatic reaction starting from a tryptophan-related compound.^[1] Before that paper, the individual compounds and intermediates were partially known, but the complete enzymatic sequence was not. Since then, two major structural studies, including a 2024 paper in Nature Communications that resolved the final enzyme at near-atomic level, have filled in the mechanical details of how each step actually works.

This article covers the steps of the pathway in depth: what each enzyme does, what intermediate compound each step produces, and why the final molecule is psilocybin rather than something else. For a broader overview of how mushrooms make psilocybin and the evolutionary story behind why certain mushrooms evolved this chemistry, the cluster overview article covers that ground. For the genetics of the gene cluster that encodes all four enzymes, see The Psilocybin Gene Cluster: Genetics of Magic Mushrooms.

Why Tryptophan? The Common Amino Acid at the Start of an Unusual Journey

Tryptophan sits at the center of several important chemical pathways in biology. In animals, the enzyme tryptophan hydroxylase converts tryptophan into 5-hydroxytryptophan, which then becomes serotonin. In mushrooms, a different enzyme, PsiD, starts a divergent sequence that ultimately produces psilocybin.

The two pathways share the same starting point because tryptophan is chemically well-suited as a precursor for bioactive molecules. Its structure includes an indole ring, a bicyclic carbon structure that appears in serotonin, melatonin, psilocybin, and dozens of other biologically active compounds. That shared scaffold is part of why psilocybin ultimately acts on serotonin receptors in the brain, despite being produced by a mushroom rather than an animal. The molecule looks enough like serotonin, structurally, that it fits the same binding site.

Fungi do not use tryptophan for serotonin. Mushrooms use tryptophan for other nitrogen-containing ring compounds, and in psilocybin-producing species, the first enzyme in the psilocybin pathway redirects tryptophan into a four-step sequence that never appears in animal biochemistry.

The Five Steps at a Glance

The tryptophan-to-psilocybin pathway completes in five reactions, each catalyzed by a specific enzyme:

1. Tryptophan → Tryptamine: PsiD removes the carboxyl group from tryptophan, releasing CO₂.
2. Tryptamine → 4-Hydroxytryptamine: PsiH adds a hydroxyl group to carbon position 4 of the ring.
3. 4-Hydroxytryptamine → Norbaeocystin: PsiK attaches a phosphate group, using ATP as the phosphate source.
4. Norbaeocystin → Baeocystin: PsiM adds the first methyl group to the nitrogen atom.
5. Baeocystin → Psilocybin: PsiM adds the second methyl group to complete psilocybin.

All five reactions were demonstrated by Fricke and colleagues in a single 2017 paper using four purified enzymes from Psilocybe cubensis.^[1] Note that step 5 uses the same enzyme as step 4 — PsiM performs two sequential methylations, not one.

Step 1: How PsiD Removes a Carbon Group From Tryptophan

PsiD is a decarboxylase. Its job is to remove the carboxyl group from tryptophan. A carboxyl group is a carbon-oxygen pair (COOH) attached to the main chain of most amino acids. When PsiD removes it, it leaves as CO₂ gas, and the remaining molecule is tryptamine.

Tryptamine itself is not psychoactive. It is a basic indole compound found in many plants and fungi in small quantities. In its unmodified form, tryptamine binds weakly to serotonin receptors and is broken down quickly by the monoamine oxidase enzymes that patrol the bloodstream. The subsequent steps in the psilocybin pathway transform tryptamine into something substantially more biologically active.

PsiD belongs to a class of enzymes called aromatic amino acid decarboxylases. The same enzyme class appears in animal nervous systems, where DOPA decarboxylase converts L-DOPA to dopamine and 5-hydroxytryptophan to serotonin. Fungi evolved an analogous enzyme for a different chemical purpose, beginning a pathway that diverges sharply from the animal chemistry that uses the same starting point.

Step 2: How PsiH Installs the 4-Hydroxy Group (This Is What Makes It Psychedelic)

PsiH is a hydroxylase. It adds a hydroxyl group, a simple oxygen-hydrogen unit (OH), to a specific position on the tryptamine ring: carbon position 4. The product is 4-hydroxytryptamine.

This step is arguably the most important in the entire pathway. The presence of a hydroxyl group at exactly position 4 of the indole ring is what gives psilocybin and psilocin their high affinity for the serotonin 5-HT2A receptor, the molecular target responsible for psychedelic effects. Plain tryptamine, without this 4-hydroxy group, does not bind meaningfully to the 5-HT2A receptor. Add the 4-hydroxy group, and the binding affinity increases dramatically. For more on how this structural feature drives psilocybin's effects in the brain, see Psilocybin and the 5-HT2A Receptor: The Key to Psychedelic Effects.

PsiH is a cytochrome P450 enzyme, a large family of oxidizing enzymes found across virtually all life forms. In animals, cytochrome P450 enzymes are responsible for metabolizing drugs in the liver. In Psilocybe cubensis, PsiH uses the same enzyme architecture for an entirely different biological purpose: constructing a psychedelic compound.

Step 3: How PsiK Creates the First Named Intermediate — Norbaeocystin

PsiK is a kinase. Its job is to attach a phosphate group to 4-hydroxytryptamine, using ATP as the phosphate source. ATP is the cell's primary energy currency; kinases borrow its phosphate group and attach it to target molecules. The product is norbaeocystin.

Norbaeocystin is the first compound in the psilocybin pathway that has its own established common name. It is not merely a theoretical step — a 2021 stability study by Gotvaldová and colleagues confirmed that norbaeocystin is present as a real compound in fresh Psilocybe cubensis biomass, alongside the other intermediates.^[2]

The phosphate group attached by PsiK does two things. It substantially increases the water solubility of the molecule, which matters for transport within the mushroom cell. And it provides a stable "pro-drug" form: in the human body, intestinal phosphatases (enzymes that remove phosphate tags) convert psilocybin into psilocin, which is the actually active molecule. Psilocybin itself is not biologically active until that phosphate group is removed. Norbaeocystin, the phosphorylated form produced at step 3, is therefore carrying the same stability advantage even before the methyl groups are added in steps 4 and 5.

Steps 4 and 5: PsiM's Double Methylation — How One Enzyme Makes Two Moves

PsiM is a methyltransferase. It borrows methyl groups, small carbon-hydrogen units (CH₃), from a molecule called S-adenosylmethionine (SAM) and attaches them to the nitrogen atom of the compound it is processing. This is called N-methylation.

SAM is a common methyl donor used in dozens of biological methylation reactions throughout biology, from gene regulation to neurotransmitter synthesis. Every time PsiM performs a methylation, it consumes one SAM molecule.

The key fact about PsiM is that it performs this reaction twice, in sequence. The first methylation converts norbaeocystin into baeocystin — one methyl group added to the nitrogen. The second methylation converts baeocystin into psilocybin — a second methyl group added to the nitrogen. The product, psilocybin, is therefore a dimethylated compound (two methyl groups on the nitrogen), while its precursors norbaeocystin and baeocystin are unmethylated and monomethylated respectively.

A 2023 computational analysis of all four psilocybin biosynthesis enzymes identified PsiM as the rate-limiting step in the pathway.^[3] Irvine, Tyler, and Delgoda used in silico structural modeling to assess substrate specificity, active site geometry, and reaction rates across all four enzymes. PsiM processes two substrates sequentially rather than one, it requires SAM as a cofactor for each reaction, and its active site geometry presents the most constrained kinetics of the four enzymes. This bottleneck identification matters for bioengineering applications: improving psilocybin yield in microbial production systems requires addressing PsiM's throughput first.

The 2024 Discovery: Why PsiM Stops at Psilocybin and Cannot Go Further

Some mushroom species produce aeruginascin, a trimethylated compound (three methyl groups on the nitrogen, rather than two). This raises the question: why does PsiM stop at two methylations and not perform a third?

In 2024, Hudspeth and colleagues solved this problem at atomic resolution.^[4] Their crystal structure of PsiM, resolved to 0.9 Ångströms (this level of precision shows individual atoms and their bond geometry), revealed the structural basis of the two-methylation limit.

PsiM evolved from METTL16, an enzyme whose normal job is to add methyl groups to RNA molecules inside cells. METTL16 is part of the RNA methyltransferase family. At some point in evolutionary history, a copy of the gene encoding METTL16 was repurposed in the psilocybin-producing fungal lineage to instead methylate the small-molecule intermediates in the biosynthetic pathway. PsiM retained the overall structural scaffold of METTL16, including its active site geometry.

That METTL16-derived geometry is precisely what limits PsiM to two methylations. The active site can accommodate the dimethylated substrate baeocystin and position a SAM molecule correctly to perform the second methylation. But the structural constraints of the active site cavity mean a third SAM molecule cannot enter and be positioned correctly after baeocystin has already been dimethylated. The geometry physically blocks the third methylation.

Mushrooms that produce aeruginascin (such as Inocybe aeruginascens) do not do so by "running PsiM one more time." They have a different, functionally distinct methylation mechanism for producing the trimethylated product. PsiM and the aeruginascin-producing enzyme are not the same gene. For a closer look at aeruginascin itself and which species produce it, see Aeruginascin: The Compound That May Make Some Mushrooms "Friendlier".

The Hudspeth structural finding also resolved the evolutionary origin of PsiM in a way no prior study had. Understanding that PsiM is a repurposed RNA methyltransferase explains both its function and its structural constraints in a single mechanism. The work was published in Nature Communications.

Baeocystin and Norbaeocystin: Found in Real Mushrooms, Not Just Reaction Tubes

The pathway intermediates norbaeocystin and baeocystin are sometimes dismissed as theoretical stepping stones. Gotvaldová and colleagues' 2021 stability study dispels that framing directly.^[2]

Gotvaldová's group measured the concentrations and stability of psilocybin and its four analogs — including baeocystin and norbaeocystin — in fresh Psilocybe cubensis biomass. Both baeocystin and norbaeocystin were present. They are not merely transient transition states that exist only during the enzymatic reaction; they accumulate in mushroom tissue as genuine metabolites. This means PsiM's reaction in a living mushroom does not convert every molecule of norbaeocystin to psilocybin. Some molecules stall at baeocystin. Some stall at norbaeocystin.

The concentrations of these intermediates are lower than psilocybin — psilocybin is the dominant product in most strains — but the intermediates are biologically real. This has direct relevance for the "entourage effect" hypothesis, the idea that the minor tryptamine compounds in mushrooms collectively contribute to the overall pharmacological profile rather than psilocybin acting alone. For the evidence on whether these minor tryptamines actually matter, see The Entourage Effect in Magic Mushrooms: Do Minor Tryptamines Matter?.

Baeocystin has been the subject of a modest amount of independent pharmacological investigation, though the evidence base for its effects is substantially smaller than the evidence for psilocybin. What the biosynthesis data establishes is that baeocystin is a structural intermediate in a well-characterized pathway, not a separate chemical lineage.

Why the Pathway Discovery Matters Beyond Mycology

The 2017 Fricke characterization did more than describe how mushrooms make psilocybin. It demonstrated that the same chemistry could be performed outside the mushroom, using purified enzymes in a test tube.^[1] That in vitro demonstration was the conceptual step that opened pharmaceutical-scale psilocybin production.

Once all four enzyme-coding genes were identified, researchers could express them in microorganisms — E. coli, yeast — that are far easier to grow at industrial scale than psychedelic mushrooms. The biosynthetic pathway encoded in four genes becomes a production system encoded in a microbial fermentation vessel. Clinical-grade psilocybin for FDA trials does not need to come from thousands of kilograms of dried mushrooms when it can be produced through controlled microbial fermentation.

The bottleneck analysis by Irvine and colleagues (PsiM as the rate-limiting enzyme) gives bioengineers a specific target.^[3] Rational engineering of the PsiM active site to improve throughput without disrupting its two-methylation specificity is a tractable problem now that the 2024 crystal structure from Hudspeth provides atomic-level geometry.^[4]

The full pharmaceutical and therapeutic context of what psilocybin does once it is produced and administered, including how it interacts with the 5-HT2A receptor and what downstream effects follow, is covered in related articles. The pathway described here explains how psilocybin gets made. What happens next is a separate and equally detailed story.

For the species context of where this pathway evolved, including which mushroom varieties contain the most psilocybin and how strain genetics influence compound levels, see Psilocybe cubensis: The World's Most Cultivated Magic Mushroom.

The Bottom Line

Mushrooms synthesize psilocybin from tryptophan in five enzymatic steps using four enzymes: PsiD removes a carbon group to make tryptamine, PsiH adds the hydroxyl group that makes the molecule pharmacologically active, PsiK adds a stabilizing phosphate group to create norbaeocystin, and PsiM performs two sequential methyl additions to produce first baeocystin and then psilocybin. A 2024 atomic-resolution crystal structure of PsiM resolved why the pathway stops at exactly two methylations, tracing the structural constraint to PsiM's evolutionary origin as a repurposed RNA methyltransferase.

Frequently Asked Questions

What are the steps in converting tryptophan to psilocybin?

There are five steps: (1) PsiD converts tryptophan to tryptamine by removing CO₂; (2) PsiH converts tryptamine to 4-hydroxytryptamine by adding a hydroxyl group at carbon position 4; (3) PsiK converts 4-hydroxytryptamine to norbaeocystin by attaching a phosphate group; (4) PsiM converts norbaeocystin to baeocystin by adding one methyl group; (5) PsiM converts baeocystin to psilocybin by adding a second methyl group. Fricke and colleagues demonstrated all five steps enzymatically in 2017, using four purified enzymes from Psilocybe cubensis.

What is the role of each enzyme in psilocybin biosynthesis?

PsiD is a decarboxylase — it removes the carboxyl group from tryptophan to produce tryptamine. PsiH is a hydroxylase — it adds a hydroxyl group to carbon position 4 of tryptamine to produce 4-hydroxytryptamine. PsiK is a kinase — it attaches a phosphate group to produce norbaeocystin, using ATP as the phosphate source. PsiM is a methyltransferase — it adds two successive methyl groups (from SAM) to produce first baeocystin and then psilocybin. PsiM is the only enzyme that catalyzes two different steps in the pathway.

What are the intermediates in psilocybin synthesis?

Four intermediates are produced between tryptophan and psilocybin: tryptamine (after PsiD), 4-hydroxytryptamine (after PsiH), norbaeocystin (after PsiK), and baeocystin (after PsiM's first methylation). Norbaeocystin and baeocystin are not merely theoretical stepping stones — a 2021 study by Gotvaldová and colleagues confirmed both are present as real compounds in fresh Psilocybe cubensis biomass, meaning the PsiM reaction leaves a fraction of molecules at intermediate stages rather than converting all substrate to psilocybin.

What is norbaeocystin?

Norbaeocystin is the phosphorylated form of 4-hydroxytryptamine, produced when PsiK attaches a phosphate group in step 3 of the psilocybin biosynthetic pathway. It is the unmethylated precursor to baeocystin and psilocybin. Norbaeocystin is present as a real compound in Psilocybe cubensis biomass (Gotvaldová et al., 2021) and has structural similarities to psilocybin, differing by the absence of both methyl groups on its nitrogen atom.

What is baeocystin and how does it relate to psilocybin?

Baeocystin is the monomethylated intermediate produced when PsiM performs its first methylation on norbaeocystin. It is one methyl group short of psilocybin. Like psilocybin, baeocystin carries a phosphate group and a 4-hydroxy group — it differs only in having one methyl group on its nitrogen instead of two. Baeocystin is found in real mushroom tissue (Gotvaldová et al., 2021) and has been studied as a minor tryptamine in its own right, though the evidence base for its specific pharmacological effects is far smaller than for psilocybin.

Why can't mushrooms make aeruginascin from psilocybin?

Aeruginascin is the trimethylated version of psilocybin (three methyl groups on the nitrogen, rather than two). PsiM physically cannot produce aeruginascin because its active site geometry, inherited from the RNA methyltransferase METTL16 from which it evolved, can accommodate two sequential SAM molecules but not a third. This structural constraint was resolved in 2024 by Hudspeth and colleagues using atomic-resolution crystallography. Species that produce aeruginascin — such as Inocybe aeruginascens — do so through a different enzyme, not by running PsiM an additional time.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.